Cargando…

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622648/ https://www.ncbi.nlm.nih.gov/pubmed/25760767 http://dx.doi.org/10.1080/19420862.2015.1007813

Ejemplares similares

Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells
por: Gruijs, Mandy, et al.
Publicado: (2022)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Novel human antibody therapeutics: The age of the Umabs
por: Ruuls, Sigrid R, et al.
Publicado: (2008)

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
por: van der Veer, M S, et al.
Publicado: (2011)

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice
por: Braster, Rens, et al.
Publicado: (2017)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020)

P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023)

The antiviral activity of antibodies in vitro and in vivo
por: Parren, Paul W.H.I., et al.
Publicado: (2001)

Monoclonal antibody‐mediated killing of tumour cells by neutrophils
por: Heemskerk, Niels, et al.
Publicado: (2018)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry
por: Parren, Paul W.H.I., et al.
Publicado: (2013)

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
por: Naicker, Serika D, et al.
Publicado: (2021)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion
por: Saengsirinavin, Aim-on, et al.
Publicado: (2021)

Influenza-Specific Antibody-Dependent Phagocytosis
por: Ana-Sosa-Batiz, Fernanda, et al.
Publicado: (2016)

Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy
por: Gül, Nuray, et al.
Publicado: (2014)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
por: Casneuf, Tineke, et al.
Publicado: (2020)

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models
por: Labrijn, Aran F., et al.
Publicado: (2017)

PHAGOCYTOSIS OF BACTERIA IN THE ABSENCE OF ANTIBODY AND THE EFFECT OF PHYSICAL SURFACE : A REINVESTIGATION OF "SURFACE PHAGOCYTOSIS"
por: Lerner, Edwin M.
Publicado: (1956)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
por: Gangat, Naseema, et al.
Publicado: (2022)

The present and future of immunocytokines for cancer treatment
por: Gout, Dennis Y., et al.
Publicado: (2022)

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap
por: Rosati, Sara, et al.
Publicado: (2013)

Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
por: Tay, Matthew Zirui, et al.
Publicado: (2019)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
por: Vidal-Crespo, Anna, et al.
Publicado: (2020)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody
por: Lin, Mei-Hwa, et al.
Publicado: (2017)

Prebiotic galactooligosaccharides activate mucin and pectic galactan utilization pathways in the human gut symbiont Bacteroides thetaiotaomicron
por: Lammerts van Bueren, Alicia, et al.
Publicado: (2017)

Structural Identity of Galactooligosaccharide Molecules Selectively Utilized by Single Cultures of Probiotic Bacterial Strains
por: Böger, Markus, et al.
Publicado: (2019)

HIC2 regulates isoform switching during maturation of the cardiovascular system
por: Dykes, Iain M., et al.
Publicado: (2018)

Draft Genome Sequence of Lactobacillus reuteri 121, a Source of α-Glucan and β-Fructan Exopolysaccharides
por: Gangoiti, Joana, et al.
Publicado: (2017)

Corrigendum to “HIC2 regulates isoform switching during maturation of the cardiovascular system” [Journal of Molecular and Cellular Cardiology volume 114 (2018) P29-37/ https://doi.org/10.1016/j.yjmcc.2017.10.007]
por: Dykes, Iain M., et al.
Publicado: (2023)

Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA
por: Almagro, Juan Carlos, et al.
Publicado: (2013)

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
por: de Jong, Rob N., et al.
Publicado: (2016)

Disappearance of macrophage surface folds after antibody-dependent phagocytosis
Publicado: (1981)

CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis
por: Kojima, Yoko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_272hrn1eace0h7k2fsbmtknepn